サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：プラスミドDNA受託製造の世界市場－規模・シェア・動向分析：用途別（細胞・遺伝子治療、免疫治療）、治療領域別（がん、感染症）、エンドユーザー別、地域別、セグメント予測（2023年～2030年）
市場調査レポート
商品コード
1171039

プラスミドDNA受託製造の世界市場－規模・シェア・動向分析：用途別（細胞・遺伝子治療、免疫治療）、治療領域別（がん、感染症）、エンドユーザー別、地域別、セグメント予測（2023年～2030年）

Plasmid DNA Contract Manufacturing Market Size, Share & Trends Analysis Report By Application (Cell & Gene Therapy, Immunotherapy), By Therapeutic Area (Cancer, Infectious Diseases), By End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 275 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
プラスミドDNA受託製造の世界市場－規模・シェア・動向分析：用途別（細胞・遺伝子治療、免疫治療）、治療領域別（がん、感染症）、エンドユーザー別、地域別、セグメント予測（2023年～2030年）
出版日: 2022年11月22日
発行: Grand View Research
ページ情報: 英文 275 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のプラスミドDNA受託製造の市場規模は、2023年から2030年までに19.3%のCAGRで成長し、2030年に11億1,750万米ドルに達すると予測されています。

細胞・遺伝子治療の人気の高まり、慢性疾患の増加、プラスミドDNAの医療分野における幅広い用途は、市場成長の主な要因となっています。

当レポートでは、世界のプラスミドDNA受託製造市場について調査しており、市場展望、市場分析、競合情勢など、包括的な情報を提供しています。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
    • 用途
    • 治療領域
    • エンドユーザー
    • 地域範囲
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • GVRの内部データベース
    • 2次情報
    • 1次調査
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の策定と検証
  • モデルの詳細
    • コモディティフロー分析（モデル1）
    • 数量価格分析（モデル2）
  • 2次情報リスト
  • 1次情報のリスト
  • 目的

第2章 エグゼクティブサマリー

  • 市場の展望

第3章 プラスミドDNA受託製造市場の変数、動向、範囲

  • 市場系列の展望
    • 親会社の市場展望
    • 関連/補助的な市場の展望
  • 市場力学
    • 市場促進要因分析
      • 病気の有病率の増加
      • 調査研究への投資の増加
      • 遺伝子治療の人気の高まり
    • 市場抑制要因分析
      • 特定の新興諸国における製造のための高度なインフラストラクチャの欠如
      • 受託製造に伴う品質問題
    • COVID-19の影響と回復の分析
    • ヒートマップ分析
    • 主要取引と戦略的提携分析
    • 業界分析－ポーターのファイブフォース分析
    • PESTLE分析

第4章 プラスミドDNA受託製造市場：用途のセグメント分析

  • プラスミドDNA受託製造市場：定義と範囲
  • プラスミドDNA受託製造市場：用途の市場シェア分析（2022年および2030年）
    • 遺伝子治療
    • 免疫療法
    • その他

第5章 プラスミドDNA受託製造市場：治療領域のセグメント分析

  • プラスミドDNA受託製造市場：定義と範囲
  • プラスミドDNA受託製造市場：治療領域の市場シェア分析（2022年および2030年）
    • がん
    • 感染症
    • 自己免疫疾患
    • 心血管疾患
    • その他

第6章 プラスミドDNA受託製造市場：エンドユーザーのセグメント分析

  • プラスミドDNA受託製造市場：定義と範囲
  • プラスミドDNA受託製造市場：エンドユーザーの市場シェア分析（2022年および2030年）
    • 製薬およびバイオテクノロジー企業
    • 研究機関

第7章 プラスミドDNA受託製造市場：地域分析

  • プラスミドDNA受託製造市場：地域の市場シェア分析（2022年および2030年）
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
    • その他のEU
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • タイ
    • 韓国
    • その他のアジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • その他のラテンアメリカ
  • 中東・アフリカ
    • 南アフリカ
    • 南アラビア
    • アラブ首長国連邦
    • クウェート
    • その他の中東・アフリカ

第8章 競合情勢

  • プラスミドDNA受託製造市場：企業市場シェア分析（2022年および2030年）
  • 企業プロファイル
    • Lonza
    • Charles River Laboratories
    • VGXI, Inc.
    • Plasmid Factory GmbH &Co. KG
    • Boehringer Ingelheim Bioxellence
    • BioCina
    • ThermoFisher Scientific Inc.
    • VIVE Biotech
    • TriLink Biotechnologies
    • Esco Aster Pte. Ltd
図表

List of Tables

  • Table 1 List of Secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 Plasmid DNA Contract Manufacturing market snapshot (2022)
  • Fig. 10 Plasmid DNA Contract Manufacturing market segmentation
  • Fig. 11 Heat map analysis
  • Fig. 12 Parent market outlook
  • Fig. 13 Ancillary market outlook
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 18 Plasmid DNA Contract Manufacturing market Application outlook: Segment dashboard
  • Fig. 19 Plasmid DNA Contract Manufacturing market: Application movement analysis
  • Fig. 20 Cell & Gene Therapy market, 2018 - 2030 (USD Million)
  • Fig. 21 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 22 Others market, 2018 - 2030 (USD Million)
  • Fig. 23 Plasmid DNA Contract Manufacturing market Therapeutic Area outlook: Segment dashboard
  • Fig. 24 Plasmid DNA Contract Manufacturing market: Therapeutic Area movement analysis
  • Fig. 25 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 26 Infectious Diseases market, 2018 - 2030 (USD Million)
  • Fig. 27 Autoimmune Diseases market, 2018 - 2030 (USD Million)
  • Fig. 28 Cardiovascular Diseases market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Plasmid DNA Contract Manufacturing market End-user outlook: Segment dashboard
  • Fig. 31 Plasmid DNA Contract Manufacturing market: End-user movement analysis
  • Fig. 32 Pharmaceutical and Biotechnology Companies market, 2018 - 2030 (USD Million)
  • Fig. 33 Research Institutes market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional market: Key takeaways
  • Fig. 35 Plasmid DNA Contract Manufacturing market: Regional movement analysis
  • Fig. 36 North America. market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada market, 2018 - 2030 (USD Million)
  • Fig. 39 Europe market, 2018 - 2030 (USD Million)
  • Fig. 40 UK market, 2018 - 2030 (USD Million)
  • Fig. 41 Germany market, 2018 - 2030 (USD Million)
  • Fig. 42 France market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway market, 2018 - 2030 (USD Million)
  • Fig. 48 Rest of EU market, 2018 - 2030 (USD Million)
  • Fig. 49 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 50 Japan market, 2018 - 2030 (USD Million)
  • Fig. 51 China market, 2018 - 2030 (USD Million)
  • Fig. 52 India market, 2018 - 2030 (USD Million)
  • Fig. 53 Australia market, 2018 - 2030 (USD Million)
  • Fig. 54 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 55 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 56 Rest of APAC market, 2018 - 2030 (USD Million)
  • Fig. 57 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 58 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 60 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 61 Rest of LATAM market, 2018 - 2030 (USD Million)
  • Fig. 62 MEA market, 2018 - 2030 (USD Million)
  • Fig. 63 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 64 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 65 UAE market, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait market, 2018 - 2030 (USD Million)
  • Fig. 67 Rest of MEA market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-004-2

Plasmid DNA Contract Manufacturing Market Growth & Trends:

The global plasmid DNA contract manufacturing market size is expected to reach USD 1,117.5 million by 2030, registering a CAGR of 19.3%, according to a new report by Grand View Research, Inc. The growing popularity of cell & gene therapy, prevalence of chronic diseases is increasing and plasmid DNA has a wide range of uses in the healthcare sector are the key factors driving the growth of the market.

The field of gene therapy significantly broaden the treatment of viral infections, malignancies, hereditary illnesses, and immunotherapy. The therapy is, however, not yet widely used in clinical settings, and licenses have often only been given in particular countries. Examples of gene treatments include Spinraza, which is used to treat spinal muscular atrophy. However, government assistance, assuring sustainability, community involvement, enacting suitable regulatory legislation, and promoting entrepreneurship are vital to the success of any gene therapy programs in Africa. Hence, the growing adoption of gene therapy in the treatment of cancer is propelling the growth of the plasmid DNA contract manufacturing market.

However, the COVID-19 resulted into positive impact on the plasmid DNA contract manufacturing market. There was an increase in demand for vaccines during the COVID-19 pandemic. The market would certainly benefit from the efforts of biotechnology companies that produce COVID-19 vaccines made from plasmid DNA. In 2022, it is anticipated that the incidence of COVID-19 would increase, thus advancing the need for COVID-19 vaccinations. For instance, India recently became the first country in the world to approve a COVID-19 DNA plasmid vaccine. The ZyCoV-D vaccine has received the Drugs Controller General of India's emergency clearance, making it the sixth vaccine to receive approval in India. Furthermore, it is the only vaccine that has been approved for adolescents between the ages of 12 and 18. The fact that a DNA vaccination has been authorized for use in people for the first time, according to researchers from all around the world, makes the approval significant.

Plasmid DNA Contract Manufacturing Market Report Highlights:

  • Cell & gene therapy dominated the market with a revenue share of 60.3% in 2022. The growing confidence of people in the dependability, efficiency, and safety of gene treatments in the treatment of a wide range of chronic and genetic disorders drives the growth of the segment.
  • Based on therapeutic areas, cancer dominated the segment with a revenue share of 39.0% in 2022. The growing number of cancer cases increases the demand for cancer treatment therapies.
  • Pharmaceutical and Biotechnology Companies dominated the market with a revenue share of 59.2% in 2022. There is a growing demand for innovative therapies requiring plasmid DNA. The companies investing in research also help to propel the segment market.
  • Asia Pacific is anticipated to register the fastest CAGR growth of 19.9% during the forecast period. The high burden of diseases, growing cancer cases, and growing adoption of plasmid DNA for developing vaccines and drugs for various diseases are the key factors driving the growth of the market in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Application
    • 1.1.2. Therapeutic Area
    • 1.1.3. End - user
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Volume price analysis (Model 2)
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2
    • 1.9.3. Objective 3
    • 1.9.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Plasmid DNA Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing disease prevalence
      • 3.2.1.2. Growing Investments in Research Studies
      • 3.2.1.3. Growing Popularity of Gene Therapy
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of advanced infrastructure for manufacturing in certain developing countries
      • 3.2.2.2. Quality Issues associated with Contract Manufacturing
    • 3.2.3. Covid - 19 Impact & Recovery Analysis
    • 3.2.4. Heat Map Analysis
    • 3.2.5. Major Deals and Strategic Alliances Analysis
    • 3.2.6. Industry Analysis - Porter's
    • 3.2.7. PESTLE Analysis

Chapter 4. Plasmid DNA Contract Manufacturing Market: Application Segment Analysis

  • 4.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
  • 4.2. Plasmid DNA Contract Manufacturing Market: Application Market Share Analysis, 2022 & 2030
    • 4.2.1. Gene Therapy
      • 4.2.1.1. Gene Therapy Market, 2018 - 2030 (USD Million)
    • 4.2.2. Immunotherapy
      • 4.2.2.1. Immunotherapy Market, 2018 - 2030 (USD Million)
    • 4.2.3. Others
      • 4.2.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Plasmid DNA Contract Manufacturing Market: Therapeutic Area Segment Analysis

  • 5.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
  • 5.2. Plasmid DNA Contract Manufacturing Market: Therapeutic Area Market Share Analysis, 2022 & 2030
    • 5.2.1. Cancer
      • 5.2.1.1. Cancer Market, 2018 - 2030 (USD Million)
    • 5.2.2. Infectious Diseases
      • 5.2.2.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
    • 5.2.3. Autoimmune Diseases
      • 5.2.3.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
    • 5.2.4. Cardiovascular Diseases
      • 5.2.4.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
    • 5.2.5. Others
      • 5.2.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Plasmid DNA Contract Manufacturing Market: End - user Segment Analysis

  • 6.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
  • 6.2. Plasmid DNA Contract Manufacturing Market: End - user Market Share Analysis, 2022 & 2030
    • 6.2.1. Pharmaceutical and Biotechnology Companies
      • 6.2.1.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million)
    • 6.2.2. Research Institutes
      • 6.2.2.1. Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 7. Plasmid DNA Contract Manufacturing Market: Regional Analysis

  • 7.1. Plasmid DNA Contract Manufacturing Market: Regional market share analysis, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.3.4. Italy
      • 7.3.4.1. Italy Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.3.5. Spain
      • 7.3.5.1. Spain Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.3.6. Denmark
      • 7.3.6.1. Denmark Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.3.7. Sweden
      • 7.3.7.1. Sweden Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.3.9. Rest of EU
      • 7.3.9.1. Rest of EU Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.4.3. India
      • 7.4.3.1. India Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.4.4. Japan
      • 7.4.4.1. Japan Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. South Korea Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.4.8. Rest of APAC
      • 7.4.8.1. Rest of APAC Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.5.5. Rest of LATAM
      • 7.5.5.1. Rest of LATAM Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.6.3. South Arabia
      • 7.6.3.1. South Africa Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 7.6.6. Rest of MEA
      • 7.6.6.1. Rest of MEA Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Plasmid DNA Contract Manufacturing Market: Company market share analysis, 2022 & 2030
  • 8.2. Company Profiles
    • 8.2.1. Lonza
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Charles River Laboratories
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. VGXI, Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Plasmid Factory GmbH & Co. KG
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Boehringer Ingelheim Bioxellence
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. BioCina
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. ThermoFisher Scientific Inc.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. VIVE Biotech
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. TriLink Biotechnologies
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Esco Aster Pte. Ltd
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Service benchmarking
      • 8.2.10.4. Strategic initiatives